Which company develops and produces Lynparza?

Olaparib is a targeted anti-cancer drug developed and produced by the well-known British pharmaceutical company AstraZeneca (AstraZeneca). It is the world's first PARP inhibitor approved for marketing and is mainly used to treat various tumors such as ovarian cancer, breast cancer, prostate cancer and pancreatic cancer carrying BRCA gene mutations. The advent of Lynparza marks a new stage in precision tumor treatment. Its approach of targeting the DNA repair mechanism has brought new treatment hope to some patients for whom traditional treatments are ineffective.

AstraZeneca has been deeply involved in the field of oncology for a long time. Lynparza is a star product developed in cooperation with the American biotechnology company Array BioPharma (now a subsidiary of Pfizer). The drug was initially approved by the U.S. FDA in 2014 for the treatment of advanced ovarian cancer. Since then, its indications have been continuously expanded, and it has been approved by many countries for first-line maintenance treatment or multi-line treatment, with increasingly broad clinical coverage. AstraZeneca also continues to promote its registration and promotion in the Chinese market.

The research and development of Lynparza is based on the principle of "synthetic lethality", that is, by inhibiting the PARP enzyme, it blocks the repair of damaged DNA in tumor cells, and is especially sensitive to cancer cells with BRCA1/2 gene mutations. Normal cells still retain other repair mechanisms, so side effects are relatively controllable. This mechanism of action not only improves the targeting of treatment, but also reduces the systemic toxicity caused by traditional chemotherapy and improves patients' quality of life.

In general, olaparib is developed and produced by AstraZeneca and is one of the most widely used PARP inhibitors in the world. Its successful launch has promoted the development of precision cancer medicine and also inspired the research and development of other similar drugs. With the accumulation of more clinical data and in-depth research on treatment combination strategies, olaparib is expected to play a role in the treatment of more types of cancer in the future.

Reference materials:https://www.lynparza.com/